Monte Rosa Therapeutics Presents Preclinical Data Of MRT-8102 At ACR Convergence 2026

Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the presentation of preclinical data showing that MRT-8102, a NEK7-directed MGD, inhibited NLRP3 inflammasome activity in human experimental systems and reduced inflammation in a rabbit model of gouty arthritis, supporting the Company’s planned Phase 2 study in patients with gout. The data are being presented at ACR Convergence 2026, being held November 6-11 in Orlando, FL.